‘Medicaid best price’ changes aimed at value-based gene therapy contracts -U.S. agency
Proposed changes to requirements that
state-run Medicaid programs are given the best drug prices would
clear the way for commercial health insurers to enter into
“value-based” payment schemes, the U.S. Centers for Medicare &
Medicaid Services said on Wednesday.
state-run Medicaid programs are given the best drug prices would
clear the way for commercial health insurers to enter into
“value-based” payment schemes, the U.S. Centers for Medicare &
Medicaid Services said on Wednesday.
Posted by Reuters
